key: cord-0927046-cvvt5kri
authors: Zhao, Shi; Wang, Kai; Chong, Marc K.C.; Musa, Salihu S; He, Mu; Han, Lefei; He, Daihai; Wang, Maggie H.
title: The non-pharmaceutical interventions may affect the advantage in transmission of mutated variants during epidemics: A conceptual model for COVID-19
date: 2022-03-21
journal: J Theor Biol
DOI: 10.1016/j.jtbi.2022.111105
sha: b29d323fec24313cf48d1ece5916c82fb2eda06c
doc_id: 927046
cord_uid: cvvt5kri

As the COVID-19 pandemic continues, genetic mutations in SARS-CoV-2 emerge, and some of them are found more contagious than the previously identified strains, acting as the major mechanism for many large-scale epidemics. The transmission advantage of mutated variants is widely believed as an innate biological feature that cannot be altered by artificial factors. In this study, we explore how non-pharmaceutical interventions (NPI) may affect transmission advantage. A two-strain compartmental epidemic model is proposed and simulated to investigate the biological mechanism of the relationships among different NPIs, the changes in transmissibility of each strain and transmission advantage. Although the NPIs are effective in flattening the epidemic curve, we demonstrate that NPIs probably lead to a decline in transmission advantage, which is likely to occur if the NPIs become intensive. Our findings uncover the mechanistic relationship between NPIs and transmission advantage dynamically, and highlight the important role of NPIs not only in controlling the intensity of epidemics but also in showing or even containing the growth of the proportion of mutated variants.

The coronavirus disease 2019 , caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1] , poses a serious threat to global health [2, 3] . The control of COVID-19 requires the knowledge of the factors that affect the transmission process [4, 5] , e.g., virus mutation is one of the major challenges [6, 7] . For instance, around September 2020, genetic variants in B.1.1.7 lineage were firstly detected in the United Kingdom (UK) [8] , then spread to otherwhere globally, and trended to reach fixation rapidly in many places, e.g., South Africa [9] , Brazil [10] , the US [11] , and the UK [12, 13] . In Brazil, the variants in P.1 lineage, or the variant of concern 202101/02 [14] , become prevalent in many places including the UK and Brazil [15] . In India, the recent B.1.617 lineage emerged and resulted in large numbers of case and deaths locally, which is considered as a potential risk for many other places globally. These emerging variants may affect the epidemiological characteristics of COVID-19 [16, 17] , and the protective effects of vaccines in use or under development [18] [19] [20] [21] [22] .

For a mutated variant that may be more infectious, one of the key investigations is to find how much more transmissible are these variants than another type of variants, typically the predecessor (original) variants. The increase in the transmissibility attributed to the mutated variants is named transmission advantage, which is a relative quantity measuring the fitness of pathogen at a population scale. Epidemiological studies reported transmission advantage in many of the mutated SARS-CoV-2 variants [12, 13, [23] [24] [25] [26] , which is considered as the major reason for the large-scale outbreaks in many places despite the controlling efforts implemented previously. Regardless of the widely implemented non-pharmaceutical interventions (NPI), which are adopted to mitigate epidemics, the mutated variants continuously bring challenges to COVID-19 control. It is widely believed (and adopted) that the transmission advantage of a mutated variant is a biological feature, which holds constantly and cannot be altered by artificial factors. However, interestingly, a recent ecological study reported that the transmission advantage of B.1.1.7 variants declined in England around December 2020 empirically [27] , which coincides with numbers of intensive control measures implemented simultaneously, e.g., social distancing and regional lockdown. Inspired by this coincidence, we suspect that NPIs play a role in affecting the transmission advantage.

To explore how NPIs may determine transmission advantage, we formulate a classic twostrain compartmental model to investigate the biological mechanism of the relationship between different NPIs and the change in transmissibility of each strain. We simulate this model to demonstrate that several types of NPIs could affect the effective transmission advantage dynamically under various scenarios accounting for the impacts of each NPI.

We develop a compartmental model based on the classic susceptible-exposed-infectiousremoved ('SEIR') modelling structure. The susceptible population is denoted by S. The infections are divided into 2 stages including exposed (E) and infectious (A and I) cases. Specifically, the infections in class E are corresponding to the cases during latent period (σ −1 ). After the latent period, we consider 2 classes of infectious cases including asymptomatic or with sub-clinical conditions (A), and symptomatic (I) cases, both of whom are infectious. The removed (by recovery or death) population is denoted by R.

individuals at an effective contact rate (or transmission rate) β. All infected individuals join class E immediately after infection, and then become infectious by leaving E at a transition rate σ, which is the reciprocal of the latent period. For the infectious cases, we model a proportion q of cases are asymptomatic (A), where q is the asymptomatic ratio, and thus (1 − q) of cases are symptomatic (I).

Eventually, all cases in A and I will either recover or die (and no longer infectious) at a transition rate γ, which is the reciprocal of the infectious period. Hence, there are 2 transition pathways 'S → E → A → R' and 'S → E → I → R' considered.

For the term β, we consider the same effective contact rate for the asymptomatic and symptomatic cases merely for simplicity. Complex scenarios can be extended by considering different transmission characteristics of asymptomatic and symptomatic cases, e.g., an asymptomatic case is partially infectious as a symptomatic case by a constant factor. In addition, the presymptomatic transmission period is considered as a part of infectious period (γ −1 ), and thus the precise interpretation of I is the individuals who (may not yet but) develop symptoms eventually.

Alternatively, a separated pre-symptomatic compartment can be modelled to consider this issue, which complicates the formulation. Note that when the latent period approaches the incubation period, the pre-symptomatic transmission period will vanish. We remark that the simple settings adopted here will not change our conclusion.

For the cases, i.e., those in E, A, or I classes, we consider 2 types of variants as the pathogen of disease that are indicated by subscript '1' for the original variant, and '2' for the newly emerged (mutated) variant. Comparing against the original type, we consider several epidemiological characteristics of mutated variants that are different from the original. They include  a change in the effective contact rate, or transmission rate, (β) by a factor ,  a change in the asymptomatic ratio (q) by a factor , and  a change in the infectious period (γ −1 ) by a factor .

All these 3 factors are positive (> 0). Specially, for the range of , it is subject to the condition that , such that the epidemiological meaning of asymptomatic ratio holds.

For interpretation, the factor is the relative ratio of contagion (or infectivity) for the second type (new) against first type (original) of variants. The factor is the relative ratio of being asymptomatic for the second type against first type of variants. The is the relative ratio of 1 recovery or death for the second type against first type of variants. In other words, the new variants prolong (or shorten) the infectious period by the factor . When any factor equals to 1, the corresponding epidemiological parameters are indifferent for the 2 types of variants.

The differences in these epidemiological characteristics were reported in literature among different SARS-CoV-2 variants for infectivity [28] [29] [30] , clinical severity or asymptomatic ratio [31] , and time interval between transmission generations [32] [33] [34] , as well as other features not included in the modelling study.

We formulate the two-strain epidemic model as an ordinary differential equation (ODE) system expressed in Eqn (1) .

Straightforwardly, for the total population N = S + E 1 + E 2 + A 1 + A 2 + I 1 + I 2 + R, we have , This basic but elegant model includes several simplifying assumptions, such as exponential distributions of both latent and infectious periods, homogeneous mixing and long-lasting immunity after recovery. For convenience, we ignore co-infection, which is rarely reported, and re-infection, which occurs at a low rate with a long gap between two infections, by another variants. Since the infection fatality ratio of COVID-19 is relatively low, which is estimated from 0.7% to 1.3% among all SARS-CoV-2 infections [35, 36] , we assume all infections will eventually recovery for simplicity.

The natural birth and death of human are also neglected since the effects of them are minor comparing to the transmission dynamics of COVID-19. Considering the 'trade-off' between the transmission rate (infectivity) and disease-induced death rate (virulence) [37] , different infection fatality ratio can be further considered by setting additional ratio parameters to class R, which was omitted in this study. Although some of the assumptions are probably 'unrealistic', the system in Eqn

(1) provides a parsimonious approximation of the reality, which allows us to capture and investigate the general patterns and dynamics of COVID-19 epidemics.

By definition, the reproduction number is the expected number of cases directly generated by one typical case in a population. As a well-studied metric that considers both reproducibility and survivability of the seed case, reproduction number is typically adopted to measure the fitness of a pathogen in maintaining its transmission [38] [39] [40] .

At the disease-free equilibrium, with a wholly susceptible population, the basic reproduction numbers, denoted by , can be formulated by using the next generation matrix approach [41] . For ℛ the first type of (i.e., original) strains, contributed by a typical asymptomatic case, i.e., A 1 ,

and contributed by a typical symptomatic case, i.e., I 1 . For the second type of (i.e., new) ℛ (I) 1 = strains, contributed by a typical asymptomatic case, i.e., A 2 , and

contributed by a typical symptomatic case, i.e., I 2 . Apparently, and , and this

is merely because we have assumed the same profiles for asymptomatic and symptomatic cases for simplicity. We remark that assuming different profiles for asymptomatic and symptomatic cases will not affect our main conclusions.

Combining the 2 parts, we have , and

. Considering the whole model, the basic reproduction number, denoted by

, is composed of and . We denote the probability that a case is infected by the first type of ℛ 0 ℛ 1 ℛ 2 strain as p, and thus, (1 − p) for the second type of strain. Then, . From the ℛ 0 = ℛ 1 + (1 -)ℛ 2 epidemiological standpoint, the term p can be interpreted as the proportion of the first type of strains among the source of infection, or as the prevalence of the active cases who are infected by the first (original) type of strains. Straightforwardly, when the second (new) type of strain is absent, i.e., p = 1, the basic reproduction number becomes β/γ, which is equivalent to that of the classic susceptibleinfectious-removed ('SIR') model. By contrast to , the effective reproduction number, denoted by , is commonly adopted ℛ 0 ℛ eff when accounting for the depletion of the susceptible population. We have , which is less ℛ eff = ℛ 0 • than (or equal to) by definition. Since S is time-varying during the course of an epidemic, is ℛ 0 ℛ eff also considered as a time-varying metric. In an epidemic of infectious disease, non-pharmaceutical interventions are commonly implemented to mitigate the outbreak size. When the control measures are considered, the effective reproduction number will be reduced, which is sometimes referred to as the controlled reproduction number.

For infectious disease, the transmission advantage (η) of a pathogen against another is typically quantified by the relative fitness. Thus, the term η is defined as the ratio between two reproduction numbers, which was adopted to study the epidemics of gonorrhoeae [42] , influenza [43] , HIV [44] , and COVID-19 [23, 25, 45] . As such, for the second type against the = ℛ 2 ℛ 1 = first type of strains in a general context. Note that the term η indicates the advantage of transmission under a natural selection-free context, namely the intrinsic transmission advantage.

Specifically, the transmission advantage (of the second against first type) is

for the asymptomatic cases, and for the symptomatic cases. Hence, we have

Here, we consider the multiplicative transmission advantage, and alternatively, the (A) = (I) transmission advantage might also be defined additively [24, 25, 46] , which leads to similar conclusions and is not discussed in this study to avoid repeating.

Since the selection pressures contribute to alter the fitness, the intrinsic transmission advantage appears limited in more realistic contexts. We consider the situation that the nonpharmaceutical interventions (NPIs) are placed. The effective transmission advantage, denoted by , accounts for the effects of selection pressures from NPIs to the disease transmission, which is an eff extension of the concept of intrinsic transmission advantage. Thus, the is defined as the ratio eff between the effective reproduction numbers of the second type and first type of variants. Similar to the intrinsic transmission advantage, if the new variants are more transmissible than the eff > 1 original variants, the larger becomes the prevalence of new variants grows more rapidly, and vice eff versa.

In the remaining parts of this work, we demonstrate several scenarios that the effective transmission advantage may become time-varying when the NPIs are implemented during epidemics.

To illustrate how NPIs may affect the transmission advantage, we conduct the numerical simulations using the settings and schemes introduced in this section.

Without losing the generality, we set the values for model parameters according to the epidemiological characteristics of the COVID-19 for demonstration. The mean latent period is considered at σ −1 = 3.5 days referring to the previous estimates at 3.3 days in [47] , and from 3.4 to 3.7 in [48] . The mean infectious period is set at γ −1 = 4.0 days, which is based on the previous calculations in [3, [48] [49] [50] . We set asymptomatic ratio at q = 30% by choosing the middle point of the range from 20% to 40% estimated in [51] [52] [53] [54] .

The total population is considered at N = 1,000,000 individuals. We consider the basic , and we have . Note that in the real-would situation, the values of , and = ℛ 2 = 5.28

can be very different, and thus the assumed values in model situation are merely for illustration at a conceptual level, which not necessarily reflects the characteristics of SARS-CoV-2 variants. Other values may merely change the numerical results, but will not affect the main conclusions.

Since it is the first outbreak of COVID-19 in human history, we assume the initial susceptible population with a relatively large scale, and at S(t = 0)/N = 99% as of the start of simulation, i.e., t = 0. For the seed cases, we mimic the situation that the new variants start emerging from a low prevalence when the original variants circulate among individuals. As such, we consider 99 and 1 exposed cases infected the original (E 1 ) and new (E 2 ) variants at the initial stage, respectively. Thus, the prevalence of the new variant is 1% (= 1 − p) at the initial stage. The rest proportion (0.99%) of the population are all assigned to class R.

Using , we calculate . With the initial conditions fixed, the

We consider and simulate 5 scenarios with (or without) the implementation of NPIs. For each scenario, we simulate the epidemic models based on Eqn (1) deterministically for 120 days using the fix-time-step Euler's method with dt = 1/365. 25 year, which is equivalent to 1 day on the scale of a

year.

Under each scenario, we record the change in the model conditions due to NPIs, and extract the characteristics of transmission, including reproduction number and transmission advantage metrics, and key epidemiological outcomes, including the number of cases and proportion of each variant, from the simulation results.

We consider the scenario (#0) that NPI is absent. As the baseline scenario, scenario (#0) is One of the major impacts of NPIs is to reduce the infectivity (i.e., transmission rate β) of the sources of infection, e.g., infectors, which can be achieved by, for instance, the adoption of personal protective equipment (PPE). For instance, facemask and hand sterilizer may significantly decrease the chance of respiratory infection [62] . To investigate the impacts of infectivity reduction on transmission advantage, a fractional reduction in the infectivity is modelled. For illustration, we reduced 30%, 50% and 70% of the infectivity of both original and new variants on day 40, 60 and 80, respectively. Here, we consider changes in infectivity due to PPE are unlikely sensitivity to genetic mutations, and thus infectivity of new variants is considered equally likely to be reduced by PPE than that of original variants under scenario (#1).

Alternatively, we relax the restriction in model conditions, and consider 2 additional subscenarios that infectivity of new variants is less or more likely to be reduced by PPE than that of original variants, which is presented in Supplementary Information S1.1.

It is possible that a mutated (new) variant may potentially result in a set of clinical conditions (or symptoms) that appear different than those of the original variants. The differences in symptoms may result in different detection ratio, which also changes the isolation proportion since cases isolation (or self-isolation) is typically implemented immediately after detection by symptoms. We consider that a fraction (i.e., isolation proportion) of symptomatic cases is timely detected and then isolated. To mimic the effects of case isolation, we remove an isolation proportion of symptomatic cases directly to the recovery class (R). Note that the transition pathways for the asymptomatic cases remain unchanged, which means no isolation is applied for asymptomatic cases. For illustration, we remove 20%, 60% and 80% of the symptomatic cases infected by both original and new variants on day 40, 60 and 80, respectively.

We explore how the differences in the clinical conditions of variants and in the implementation of symptomatic case isolation shapes the profile of transmission advantage.

Alternatively, we relax the restriction in model conditions, and consider 2 additional sub-scenarios that symptomatic cases of new variants are less or more likely to be detected than those of original variants, which is presented in Supplementary Information S1.2.

Contact tracing is commonly implemented to find linked infected within transmission clusters. Under intensive contact tracing, cases can be detected timely (and followed by isolation) such that future transmission can be prevented. Here, we model the effect of early detection and isolation by directly removing the cases to the recovery class (R) immediately after detection.

Specifically, we assume the mean detection delay, or containment delay [63] , at 3.5, 2.5 and 1.5 days on day 40, 60 and 80, respectively for illustration. Thus, if the mean infectious period is larger than the mean detection delay, the mean infectious period will be changed to the mean detection delay, which mimics the case isolation after detection. This applies to both asymptomatic and symptomatic cases.

To avoid confusion, we re-visit the previous scenario (#1) for more clarification before introducing scenario (#4). In scenario (#1), the infectivity is reduced by proportionally decreasing the transmission rate β, which is considered as the effect from PPE. To clarify, we crudely decompose term β into the contact rate (denoted by b) and transmission probability per contact (denoted by α, and 0 ≤ α ≤ 1), and thus β = αb according to the classic epidemiological theory. Since the PPE will not affect the scale of term b, the reduction in infectivity under scenario (#1) is to reduce α, which also decrease β. Therefore, more specifically, the factor controls the advantage in α.

In NPI-absence situation, the transmission occurs with a high b but a low α, which reflects the general contexts of public places including workspace, market, and school. However, with social distancing, people are forced to stay at private location such as hotel and private residence, which implies a low b but a high α. The α becomes higher because social distancing increases the duration and proximity of each contact. Under scenario (#4), although the product of αb decreases, the increase in α may lead to different changing patterns of transmission advantage. Indeed, the proportion of household infections becomes more common with intensive social distancing. Note that the value of α may become remarkably high, and even close to 1, under intensive social distancing, which means if infectors are almost certain to transmit disease to their close contacts. 

h must not exceed 1. Hence, social distancing might lead to a decrease in transmission advantage due to a satiation in household transmission probability per contact. Although this explicit decomposition of public-space and household transmission was not adopted for simulation here, we remark that similar numerical outcomes can be reached, which leads to the same conclusion.

Considering However, the increases when more fraction of symptomatic cases are isolated. We also find that eff the prevalence of the new variant increases faster than the scenario without NPI, see Fig 2G. If the isolation proportion for symptomatic case becomes extremely high (e.g., 100% isolation), the value of effective transmission advantage will approach the product of . This means the transmission advantage governed by the asymptomatic ratio ( ) can be traded by eliminating the transmissibility of symptomatic cases. By contrast, if , the may decrease when more < 1 eff fraction of the symptomatic cases are isolated. The outcomes appear different if the symptomatic cases of new variants are not equally (i.e., more, or less) likely to be isolated than those of original variants. We find that the is decreased or increased dynamically depending on the different eff proportion of symptomatic cases isolation for the 2 types of variants, see Supplementary Information S1.2. However, it appears that the genetic mutations in pathogen seldomly cause any distinguishable (and detectable) difference in clinical conditions [27] , and thus symptomatic cases of new variants are equally likely to be detected (and thus isolated) than those of original variants under the scenario (#2).

Contact tracing is frequently implemented to find individuals with high risk of exposure, and prevent future transmission, see scenario (#3). Since all cases under intensive contact tracing will be detected earlier and isolated, the R eff decreases and the size of outbreak is reduced, see Fig 3. However, the decreases when the contact tracing is implemented. Here, we consider a simplified eff assumption that the contact tracing reduces the infectious periods of both variants to the same value, which matches the findings in containment delay [63] [64] [65] . In other words, each case is expected to be detected and isolated certain period (e.g. The social distancing appears one of the commonly adopted NPI against COVID-19

pandemic [66] . In scenario (#4), we highlight the increase in transmission probability per contact α despite the reduction in contact rate b as well as the overall reduction in transmission rate β, which is thus distinguished from scenario (#1). In Fig 4, the number of cases is decreased due to the impacts of social distancing. The also decreases in Fig 4C when the term α of both variants reaching 1 in eff Fig 4A. Namely, contacts who are closely connected to the source of infection (i.e., infector) are highly likely to become infected, which occurs frequently at private places. As α increasing and reaching 1, β of the 2 types of variants approaches each other and eventually converges to the same value. Thus, decreases from to , which indicates the transmission advantage controlled by eff the factor vanishes.

In this study, we demonstrated that NPIs can not only control the intensity of epidemics, but also show or even contain the growth of mutated variants' proportion through changing the transmission advantage. In the context of disease transmission, the reproduction number (R eff ) determined both cases time series and epidemic size, and strain-specific reproduction numbers determined the transmission advantage of each strain. NPIs may change the reproduction numbers of different strains to different levels, and thus both epidemic curve and transmission advantage may be altered, see the summary in Table 1 . Moreover, the change in transmission advantage due to NPIs (or sometimes not) also affects the process of viral variants establishing their dominance at the population scale through transmission. Our modelling framework conceptualized the impacts and mechanisms of (different types of) NPIs on the dynamics of transmission for different virus strains, which may further lead to a change in the selection advantage among strains.

In the practice, various types of NPIs are usually implemented simultaneously to achieve a December 2020 [27] .

Considering the symptomatic case isolation under scenario (#2), the changes in are also eff determined by the setting of . In the real-world situation, the impact of symptomatic case isolation vanishes if the asymptomatic ratios (q) are the same for both variants [27] , which means holds eff unchanged with . Under scenario (#3), contact tracing may contribute to change when = 1 eff . However, we detect no evidence about the change in infectious period (γ −1 ) attribute to the ≠ 1 genetic mutation, and the value of is probably around 1. Thus, little impact on from contact eff tracing could occur.

In all scenarios, the epidemics are controlled considering the number of cases, peaking size, and the decay time of peak, which reflects the effectiveness of NPIs. The key impacts of each type of NPI on the epidemiological parameters and effective transmission advantage are summarized qualitatively in Table 1 . By affecting , the growing patterns of the proportion of new variants, eff denoted by , are also changed to some extent. We further note that large and early susceptibility in a group of population, and decreasing fatality risk so that the infector has a chance to transmit to more individuals, which are partially discussed in [24] . Although many intrinsic features of mutated variants could bring mixed contributions to the viral fitness, the impacts of , , and , especially , are the most commonly considered scenarios in many studies of COVID-19 [12, 23, 45] , and influenza [43, 67] , which are more likely the dominant factors shaping the transmission advantage.

In scenarios (#1), (#2) and (#4), the impacts of NPIs are simulated by changing the epidemiological parameters in Eqn (1) multiplicatively. Since the transmission advantage ( or ) eff is defined as a multiplicative factor between reproduction numbers, see section 2.3, we consider that the multiplicative changes in the parameters provide a 'fair' comparison of the before and after eff the implementation of various NPIs. Alternatively, additive changes can be adopted to mimic the impacts of NPI. We note that the additive changes in parameters are more likely to results in the changes of , consider section 3.2.4 as an example. Regardless of the additive or multiplicative eff changes, we demonstrated that NPI may lead to change in the transmission advantage ( ) that eff appears differently from its intrinsic value ( ), which is likely to occur when the level of NPIs becomes intensive.

For the limitations of this study, we merely demonstrated how NPI changes over time may lead to the change in transmission advantage. We discuss that the spatial heterogeneity in the implementation of NPIs may also cause and amplify the difference in transmission advantage. For example, the transmission advantage of B.1.1.7 SARS-CoV-2 lineage appears at different scales in different regions of England [27] , and in other places [24, 68] . Aside from NPIs, other nonpharmaceutical factors, e.g., weather and pollutants, might affect the infectivity to different degrees regarding different variants. For example, although lack real-world supportive evidence, the mutations might alter the viability of viruses that become more adaptive to warm weather, which implies the changes in infectivity are different for the original and new variants as temperature increases. Recent study also reported that the transmission advantage of B.1.1.7 SARS-CoV-2 lineage appears (slightly) less than average for target individuals with ages from 10 to 30 years [24] .

As such, the NPIs having heterogeneous effects for different age groups could also lead to changes in transmission advantage. Although vaccine and other pharmaceutical measures in controlling or treating an infectious disease may affect the selection advantage of different genetic variants of the pathogen at various scales, we concentrated on the impacts of NPIs in this study, and left these possible scenarios with both pharmaceutical and non-pharmaceutical interventions for future investigations. Tables   Table 1. Qualitative summary on the key impacts of each type of NPI on the epidemiological parameters and effective transmission advantage.

impacts on scenario in this study type of NPI parameters or transmission dynamics transmission advantage (#0) 

Characteristics of SARS-CoV-2 and COVID-19

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study

Transmission routes of respiratory viruses among humans

Factors that make an infectious disease outbreak controllable

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

A single mutation in chikungunya virus affects vector specificity and epidemic potential

Emergence of a new SARS-CoV-2 variant in the UK

Introduction of the South African SARS-CoV-2 variant 501Y. V2 into the UK. The Journal of infection

Local Transmission of SARS-CoV-2 Lineage B.1.1.7, Brazil

Emergence of SARS-CoV-2 b. 1.1. 7 lineage-united states

Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom

Changes in symptomatology, re-infection and transmissibility associated with SARS-CoV-2 variant B. 1.1. 7: an ecological study

Variants: distribution of cases data: Variants of concern or under investigation: data up to

Covid-19: The E484K mutation and the risks it poses

SARS-CoV-2 Variants of Concern in the United States-Challenges and Opportunities

VOC 202012/01 Variant Is Effectively Neutralized by Antibodies Produced by Patients Infected before Its Diffusion in Italy. Viruses-Basel 2021

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccineelicited sera

SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants

Neutralization of SARS-CoV-2 lineage B. 1.1. 7 pseudovirus by BNT162b2 vaccine-elicited human sera

Reduced neutralization of SARS-CoV-2 B. 1.1. 7 variant by convalescent and vaccine sera

Shete AM et al: Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees

Quantifying the transmission advantage associated with N501Y substitution of SARS-CoV-2 in the UK: an early data-driven analysis

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Assessing transmissibility of SARS-CoV-2 lineage B. 1.1. 7 in England

Modelling the association between COVID-19 transmissibility and D614G substitution in SARS-CoV-2 spike protein: Using the surveillance data in California as an example

Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B. 1.1. 7: an ecological study. The Lancet Public Health

SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo

Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: An insight from structural data

Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study. The Lancet Infectious Diseases

Rapid Spread of the SARS-CoV-2 Variant of Concern 202012/01 in Southern Italy

Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis. The Lancet Infectious Diseases

Shorter serial intervals in SARS-CoV-2 cases with Omicron BA.1 variant compared with Delta variant, the Netherlands

Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta)

Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship

Estimates of the severity of coronavirus disease 2019: a model-based analysis

Virulence-driven trade-offs in disease transmission: A meta-analysis*. Evolution

How should we define 'fitness' for general ecological scenarios?

The construction of next-generation matrices for compartmental epidemic models

):veaa105. 41. van den Driessche P, Watmough J: Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission

Estimating the fitness cost and benefit of cefixime resistance in Neisseria gonorrhoeae to inform prescription policy: a modelling study

Monitoring the fitness of antiviral-resistant influenza strains during an epidemic: a mathematical modelling study. The Lancet Infectious diseases

Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics

Genomics and epidemiology of the P. 1 SARS-CoV-2 lineage in Manaus, Brazil

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

Estimating the time interval between transmission generations when negative values occur in the serial interval data: using COVID-19 as an example

Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)

Centre for Mathematical Modelling of Infectious Diseases C-wg: Early dynamics of transmission and control of COVID-19: a mathematical modelling study

Novel coronavirus 2019-nCoV (COVID-19): early estimation of epidemiological parameters and epidemic size estimates

Detection of SARS-CoV-2 among residents and staff members of an independent and assisted living community for older adults

Humoral immune response to SARS-CoV-2 in Iceland

Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship

Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19)

Serial Interval of COVID-19 among Publicly Reported Confirmed Cases

Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing

Spread and Impact of COVID-19 in China: A Systematic Review and Synthesis of Predictions From Transmission-Dynamic Models

The Rate of Underascertainment of Novel Coronavirus (2019-nCoV) Infection: Estimation Using Japanese Passengers Data on Evacuation Flights

Estimating the serial interval of the novel coronavirus disease (COVID-19) based on the public surveillance data in Shenzhen, China

Imitation dynamics in the mitigation of the novel coronavirus disease (COVID-19) outbreak in Wuhan

He D: A re-analysis in exploring the association between temperature and COVID-19 transmissibility: an ecological study with 154 Chinese cities

Facemasks and hand hygiene to prevent influenza transmission in households: a cluster randomized trial

Effects of proactive social distancing on COVID-19 outbreaks in 58 cities

Evolving epidemiological characteristics of COVID-19 in Hong Kong from

Quantifying the improvement in confirmation efficiency of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the early phase of the outbreak in Hong Kong in 2020

Impact of self-imposed prevention measures and short-term government-imposed social distancing on mitigating and delaying a COVID-19 epidemic: A modelling study

Population dynamics of rapid fixation in cytotoxic T lymphocyte escape mutants of influenza A

The co-circulating transmission dynamics of SARS-CoV-2 Alpha and Eta variants in Nigeria: A retrospective modeling study of COVID-19